Premier Alternatives

PAhR Therapeutics

Drug Discovery · Boston, MA · Founded 2025 · Privately Held (backing)

Operator of a clinical-stage biotechnology company intended to develop novel therapies for pulmonary arterial hypertension through innovative molecular mechanisms. PAhR Therapeutics is based in Boston, MA and was founded in 2025. It was valued at $25 million at its seed round in Jul 2025, the last priced event on record. It has raised $14 million across 1 recorded round; the latest was a $14 million seed round in Jul 2025.

PMV mark · valuation
$25.0M
Oct 2026
Priced at
its seed round
Jul 2025
Total raised
$14.0M
Last round
Seed Round
Jul 2025

PAhR Therapeutics key facts

as of Oct 2026
  • Operator of a clinical-stage biotechnology company intended to develop novel therapies for pulmonary arterial hypertension through innovative molecular mechanisms.
  • PAhR Therapeutics is valued at approximately $25.0M as of Oct 2026, set at its seed round, Jul 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $14.0M across 1 recorded rounds; the latest was Seed Round ($14.0M) in Jul 2025.
  • Notable investors include RA Capital Management, The University of Tokyo Edge Capital, AN Ventures.
  • PAhR Therapeutics has filed 1 Form D with the SEC, most recently Jul 2025 ($4.7M sold to 4 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$25.0M

Valued at $25.0M at its seed round, Jul 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of PAhR Therapeutics with a free account
  • ·Watch PAhR Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

PAhR Therapeutics funding rounds

1 rounds
Jul 2025Seed Round$14.0M▮
Full funding history →

PAhR Therapeutics valuation

PAhR Therapeutics was valued at $25 million at its seed round in Jul 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has PAhR Therapeutics raised?

PAhR Therapeutics has raised $14 million across 1 recorded round since 2025. The largest was a $14 million seed round in Jul 2025.

PAhR Therapeutics has filed 1 Form D with the SEC, most recently in Jul 2025 ($4.7 million sold to 4 investors).

PAhR Therapeutics investors

3 investors are on record for PAhR Therapeutics, including RA Capital Management, The University of Tokyo Edge Capital and AN Ventures. The seed round in Jul 2025 drew 2 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Persephone Biosciences ($37.3 million), Solarea Bio ($37 million) and Ancilia Bio ($28 million).

About PAhR Therapeutics

Operator of a clinical-stage biotechnology company intended to develop novel therapies for pulmonary arterial hypertension through innovative molecular mechanisms. The company offers cutting-edge treatments targeting the molecular pathophysiology of PAH, enabling customers to access potentially life-saving therapies that address unmet needs in PAH treatment, offering new hope where conventional options fall short.

Industry
Drug Discovery
Sector
Healthcare
HQ
Boston, MA, United States
Founded
2025
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.